Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Investor Presentation (January 2026)
25 slides from Hansa Biopharma Ab's investor presentation, January 2026
Slide 1: Corporate Presentation
® Corporate Presentation January 2026
Slide 2: Forward-looking statements
Forward-looking statements ® This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will o
Slide 3: Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform
Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform ® What is IgG Hansa’s IgG-cleaving Platform Immunoglobulin G (IgG): a protective antibody Imlifidase – proprietary, first in class IgG cleaving enzyme Transplantation / Gene Therapy: High antibody (IgG) Rapid and ta
Slide 4: Unique platform targeting serious immune mediated conditions; rapid IgG reduction
Unique platform targeting serious immune mediated conditions; rapid IgG reduction ® Provides unmatched speed in reducing IgG IgG cleaving enzymes cleave antibodies across all domains Extravascular Cell bound IgG lowering Intravascular IgG IgG IgG modalities Imlifidase HNSA-5487 FcRn inhibitor - PLEX
Slide 5: Addressing orphan / rare indications
Addressing orphan / rare indications ® THERAPEUTIC FOCUS Desensitization IDEFIRIX® conditionally approved in the EU For desensitization prior to kidney transplantation Enabling Transplantation Paradigm shift for highly sensitized kidney transplant patients Revenue generating Enabling Gene Therapy ID
Slide 6: Desensitization: Transplantation
® DESENSITIZATION Transplantation © 2026, Hansa Biopharma AB
Slide 7: Transplantation: High Unmet Need with Significant Market Potential
Transplantation: High Unmet Need with Significant Market Potential ® Pioneering breakthrough for patients Desensitization Potentially significantly larger with significant unmet medical need TRANSPLANTATION population as not all patients are Potential market opportunity > $2bn referred to the wa
Slide 8: Thousands of highly sensitized U.S. patients face indefinite dialysis
Thousands of highly sensitized U.S. patients face indefinite dialysis ® US Transplant Waitlist ~ 15% of patients are highly sensitized The US represents a significant (cPRA > 80%) market opportunity Significant ~100,000 on the wait list Unmet ~15k highly sensitized ~45,000 patients with Medical Need
Slide 9: Robust U.S. commercialization strategy established
Robust U.S. commercialization strategy established ® Concentrated Market Pricing and Reimbursement Experienced US Team ~200 adult transplant centers ~55% Medical Affairs paid by Medicare Field team with multiple years in the transplant market; SVP Medical Affairs has recent nephrology launch experie
Slide 10: Successful US ConfIdeS Phase 3 study
Successful US ConfIdeS Phase 3 study ® Highly statistically significant outcome (p<0.0001) Imlifidase Control Imlifidase Control p-value n n eGFR (mean) eGFR (mean) Primary endpoint 32 32 51.5 19.3 <0.0001 eGFR at 12 months in FAS Rank-based non-parametric analysis of eGFR at 32 32 50.0* 0* 0.0001 1
Slide 11: Long-term follow-up study showed durable graft and patient survival
Long-term follow-up study showed durable graft and patient survival ® Study Overview Extended pooled analysis from the 17-HMedIdeS-14 study A long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase Key Takeaways 82% five-year graft
Slide 12: Europe: Upcoming Milestones and Growth Initiatives
® Europe: Upcoming Milestones and Growth Initiatives EU Market Challenges Current Status in Europe Accelerating Initiatives Fragmented market Reimbursement Focus on resolving regional market Limited KOL experience 21+ markets across the EU access challenges representing 90% of the Phase 2 wi
Slide 13: Desensitization: Gene Therapy
® DESENSITIZATION Gene Therapy © 2026, Hansa Biopharma AB
Slide 14: Compelling opportunity in high-growth gene therapy sector
Compelling opportunity in high-growth gene therapy sector ® GENE THERAPY MARKET DESENSITIZATION Multiple gene therapy drugs SIGNIFICANT GROWTH EXPECTED GENE THERAPY with 10 – 40% of patients eligible who cannot be Existing $2bn+ market in 2024 treated due to AAV vector Expected to reach $23.9B by
Slide 15: Collaborating to bridge access to gene therapies for more patients
Collaborating to bridge access to gene therapies for more patients ® Indication exclusivity Duchenne Muscular Indication exclusivity Current Dystrophy (DMD) - 1/3,500 to Crigler-Najjar syndrome – partnerships 5,000 male births worldwide ultrarare condition with Limb-Girdle Muscular approximate
Slide 16: Next generation Compound – Autoimmune Focus: HNSA-5487
® Next generation Compound – Autoimmune Focus HNSA-5487 © 2026, Hansa Biopharma AB
Slide 17: Non-human host derived; Phase 1 clinical data
Non-human host derived; Phase 1 clinical data ® Data demonstrated significantly lower immunogenicity for HNSA-5487 with rapid and robust IgG reduction – targeting FDA interaction in 1H 2026 for GBS Study Overview • Double blind, randomized, placebo-controlled trial in 36 healthy volunteers received
Slide 18: Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS
Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS ® Guillain-Barré Syndrome Phase 2 Study Results A rare, acute, paralyzing, inflammatory disease of the peripheral nervous system caused by the immune Rapid overall improvement in functional system damaging ne
Slide 19: Rare disease focus; IgG mediated conditions
Rare disease focus; IgG mediated conditions ® Guillan Barre Syndrome Significant unmet medical need – nothing approved in Europe and US Europe or the US for GBS 14,108 Strong Phase 2 data with imlifidase provides basis for addressable further clinical development 18,564 Targeted FDA interaction in 1
Slide 20: Financials and Outlook
® FINANCIALS AND OUTLOOK © 2026, Hansa Biopharma AB
Slide 21: Commercial traction & financial highlights
Commercial traction & financial highlights ® IDEFIRIX® sales grew by The product is available in ~20 Ended Q3 2025 with SEK 252m On 1st of October 2025 raised +25% YTD Q3 2025 to SEK European markets, with 117 cash, proforma SEK 888m USD 71 million through clinics equipped and ~70% ($93m) post capit
Slide 22: Validated, high value pipeline with transformative milestones ahead
Validated, high value pipeline with transformative milestones ahead ® Q1 2026 Q2 2026 Q3 2026 Q4 2026 FDA ATC US BLA feedback on ConfIdeS full acceptance GBS clinical data / PDUFA development presentation Potential US date progress approval/ launch Filing for full approval with EMA Genethon Ph2 gene
Slide 23: Focused Pipeline in Desensitization and Autoimmune Diseases
® Focused Pipeline in Desensitization and Autoimmune Diseases Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Upcoming Milestone Mid 2026: EU PAES data read out Desensitization Kidney Transplantation Q1 2026: Determination of BLA acceptance by Desensitization Kidney Transplantation FDA and PDUF
Slide 24: Experienced and Proven Leadership Team
Experienced and Proven Leadership Team Proven track record delivering growth, approvals, and launches across renal, rare disease, and immunology ® Renée Aguiar-Lucander Maria Törnsén CEO COO, President US 20+ yrs rare disease leader and former investor, Successfully launched multiple orphan drugs in
Slide 25: Hansa Biopharma
IZ HAN SAP BIOPHARMA
Hansa Biopharma — Investor Presentation (January 2026) on 6ix